Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29901519 | 0.98 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL19983 | 0.98 | TRPA1 (0.31) | TRPA1 | |
| Hydrogen Sulfide SCHEMBL27732874 | 0.96 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL27611235 | 0.96 | TRPA1 (0.31) | TRPA1 | |
| Ammonia Solution, Strong SCHEMBL27596721 | 0.96 | TRPA1 (0.31) | TRPA1 | |
| Hydrochloric Acid SCHEMBL7403491 | 0.96 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL27543379 | 0.96 | TRPA1 (0.31) | TRPA1 | |
| Cycloheptane SCHEMBL27301709 | 0.92 | — | — | |
| Dimethyl Sulfoxide SCHEMBL8008395 | 0.87 | — | — | |
| Alcohol SCHEMBL27591126 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021262825-A2 | DISRUPTING LIPID SYNTHESIS: A NOVEL TARGET FOR BROAD-SPECTRUM HOST-DIRECTED ANTI-VIRULENCE THERAPEUTICS | GENETIC NETWORKS, LLC (US) | 2021-12-30 | — | — | WO | claimed |
| EP-3478658-B1 | PHARMACEUTICAL MRNA COMPOSITIONS AND METHODS FOR POTENTIATING GENE SILENCING | OLIX PHARMACEUTICALS INC (KR) | 2021-09-29 | — | — | EP | claimed |
| US-10639308-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-05-05 | — | — | US | claimed |
| US-20200087367-A1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | ACCELERON PHARMA INC. | 2020-03-19 | — | — | US | claimed |
| US-20190321388-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR POTENTIATING GENE SILENCING | OLIX PHARMACEUTICALS, INC. (KR) | 2019-10-24 | — | — | US | claimed |
| EP-2953558-B1 | EMBRYO TRANSFER CATHETER | SILLENDER MARK (AU) | 2019-08-28 | — | — | EP | claimed |
| EP-3478658-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR POTENTIATING GENE SILENCING | Olix Pharmaceuticals, Inc. (KR) | 2019-05-08 | — | — | EP | claimed |
| CN-109563037-A | Pharmaceutical compositions and methods for enhancing gene silencing | 奥利克斯医药有限公司 | 2019-04-02 | — | — | CN | claimed |
| US-10154856-B2 | Therapeutic substance transfer catheter and method | SILLENDER MARK (AU) | 2018-12-18 | — | — | US | claimed |
| WO-2018144968-A1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | ACCELERON PHARMA INC. (US) | 2018-08-09 | — | — | WO | claimed |
| EP-2953678-A1 | THERAPEUTIC SUBSTANCE TRANSFER CATHETER AND METHOD | Sillender, Mark (AU) | 2015-12-16 | — | — | EP | claimed |
| EP-2953558-A1 | EMBRYO TRANSFER CATHETER AND METHOD | Sillender, Mark (AU) | 2015-12-16 | — | — | EP | claimed |
| US-20150342642-A1 | EMBRYO TRANSFER CATHETER AND METHOD | SILLENDER MARK (US) | 2015-12-03 | — | — | US | claimed |
| WO-2015051336-A1 | COMPOSITIONS AND METHODS FOR TREATING PELVIC PAIN AND OTHER CONDITIONS | WISE DAVID (US) | 2015-04-09 | — | — | WO | claimed |
| WO-2014121332-A1 | THERAPEUTIC SUBSTANCE TRANSFER CATHETER AND METHOD | SILLENDER MARK (AU) | 2014-08-14 | — | — | WO | claimed |
| WO-2014121333-A1 | EMBRYO TRANSFER CATHETER AND METHOD | SILLENDER MARK (AU) | 2014-08-14 | — | — | WO | claimed |
| US-7851431-B2 | Treatment of actinic keratoses with calcium channel blockers | PRESCRIPTION DISPENSING LABORATORIES (US) | 2010-12-14 | — | — | US | claimed |
| US-20070027194-A1 | TREATMENT OF ACTINIC KERATOSES WITH CALCIUM CHANNEL BLOCKERS | PRESCRIPTION DISPENSING LABORATORIES | 2007-02-01 | — | — | US | claimed |
| US-20030162769-A1 | Composition and method for treating vulvodynia | EASTERLING W JERRY (US) | 2003-08-28 | — | — | US | claimed |
| US-20020156065-A1 | Medicament and method for the remediation of aberrant fibrotic tissue masses with topical calcium channel blocker preparations | EASTERLING W JERRY (US) | 2002-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087367-A1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | BMPR2, BMPR1B, BMP1 | TRPA1 4860/4885 |
| US-10639308-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | TRPA1 1746/4885 |
| US-20190321388-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR POTENTIATING GENE SILENCING | ORAI1, CACNB2, CACNB1 | TRPA1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.